Theravance Biopharma, Inc. (TBPH)
17.06
+0.02
(+0.09%)
USD |
NASDAQ |
Sep 01, 12:00
Theravance Biopharma Total Long Term Debt (Quarterly) : 60.57M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 60.57M |
| March 31, 2026 | 62.55M |
| December 31, 2025 | 64.55M |
| September 30, 2025 | 33.68M |
| June 30, 2025 | 35.56M |
| March 31, 2025 | 68.33M |
| December 31, 2024 | 39.11M |
| September 30, 2024 | 40.78M |
| June 30, 2024 | 42.44M |
| March 31, 2024 | 43.84M |
| December 31, 2023 | 45.24M |
| September 30, 2023 | 41.12M |
| June 30, 2023 | 42.52M |
| March 31, 2023 | 43.76M |
| December 31, 2022 | 45.41M |
| September 30, 2022 | 51.38M |
| June 30, 2022 | 675.34M |
| March 31, 2022 | 668.89M |
| December 31, 2021 | 669.02M |
| September 30, 2021 | 670.22M |
| June 30, 2021 | 667.28M |
| March 31, 2021 | 671.10M |
| December 31, 2020 | 666.39M |
| September 30, 2020 | 659.00M |
| June 30, 2020 | 649.32M |
| Date | Value |
|---|---|
| March 31, 2020 | 647.21M |
| December 31, 2019 | 502.77M |
| September 30, 2019 | 504.95M |
| June 30, 2019 | 503.98M |
| March 31, 2019 | 503.28M |
| December 31, 2018 | 454.35M |
| September 30, 2018 | 224.55M |
| June 30, 2018 | 224.28M |
| March 31, 2018 | 224.01M |
| December 31, 2017 | 223.75M |
| September 30, 2017 | 223.48M |
| June 30, 2017 | 223.21M |
| March 31, 2017 | 222.94M |
| December 31, 2016 | 222.68M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Zymeworks, Inc. | 265.33M |
| Viatris, Inc. | 13.51B |
| Ocular Therapeutix, Inc. | 76.26M |
| ANI Pharmaceuticals, Inc. | 610.49M |
| Corcept Therapeutics, Inc. | 7.504M |